In a 2‑day‑old male with severe hyperammonemia, how do continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF) differ in terms of solute clearance, fluid removal, and clinical suitability?

Differentiating CVVH, CVVHD, and CVVHDF in Neonatal Hyperammonemia

For a 2-day-old neonate with severe hyperammonemia, CVVHD (continuous venovenous hemodialysis) is superior to CVVH and should be your first-line continuous renal replacement therapy, as it achieves higher ammonia clearance rates through diffusion-based solute removal while maintaining hemodynamic stability. 1

Mechanism of Solute Clearance

CVVH (Continuous Venovenous Hemofiltration)

• Mechanism: Pure convection—solutes are removed by being "dragged" across the membrane with ultrafiltrate
• Clearance characteristics: Effective for both small and large molecules, but less efficient for small solutes like ammonia compared to diffusion-based methods 2
• Clearance formula: K(UF) = (Q(UF)/60) × Q(B)/(Q(B) + Q(UF)/60) 2

CVVHD (Continuous Venovenous Hemodialysis)

• Mechanism: Pure diffusion—solutes move down concentration gradients from blood to dialysate
• Clearance characteristics: Superior for small molecular weight solutes like ammonia (17 Da), urea, and creatinine 3
• Clearance formula: Kd = Q(D)/60, where clearance approximates dialysate flow rate 2
• Key advantage: At low blood flow rates typical in neonates (10-20 mL/min), CVVHD provides statistically superior clearance compared to CVVH 3

CVVHDF (Continuous Venovenous Hemodiafiltration)

• Mechanism: Combined convection + diffusion
• Clearance characteristics: Theoretically combines benefits of both, but interaction between convection and diffusion may reduce overall efficiency 2
• Clinical reality: In practice, ammonia clearance with CVVHDF shows no significant advantage over CVVH or CVVHD alone 4

Clinical Performance Data

Critical finding: A 2022 study in adult liver failure patients demonstrated no significant difference in median ammonia clearance between techniques:

• CVVH: 27 mL/min (IQR 23-32)
• CVVHD: 21 mL/min (IQR 17-28)
• CVVHDF: 20 mL/min (IQR 14-28), p=0.32 4

However, pediatric-specific data contradicts this: In neonates with low blood flow rates (60 mL/min), CVVHD achieved 15% greater urea clearance than predilution CVVH (11.3 vs 9.8 mL/min, p<0.005) 3. This difference becomes clinically significant in the hyperammonemic neonate where every minute of elevated ammonia increases neurological damage risk.

Fluid Removal Capabilities

All three modalities provide continuous, controlled fluid removal without the hemodynamic instability and osmotic shifts seen with intermittent hemodialysis 1. This is critical in neonates with hyperammonemia who often have:

• Cerebral edema
• Elevated intracranial pressure
• Hemodynamic instability

Key advantage of continuous therapy: Avoids rebound hyperammonemia that occurs with intermittent HD, reducing need for multiple dialysis sessions 1

Clinical Suitability for Neonatal Hyperammonemia

When to Choose CVVHD (First-Line)

Consensus recommendation 9: CKRT, specifically high-dose CVVHD, is the recommended first-line treatment for hyperammonemia when possible 1

Initiate when:

• Rapidly deteriorating neurological status with ammonia >150 μmol/L (256 μg/dL)
• Moderate/severe encephalopathy (lethargy, hypotonia, weak suck, constricted pupils)
• Persistently high ammonia >400 μmol/L (681 μg/dL) refractory to medical management
• Rapid rise to >300 μmol/L (511 μg/dL) within hours 1

Dosing parameters:

• Blood flow (Qb): 30-50 mL/min in neonates
• Dialysate flow (Qd): Aim for Qd/Qb ratio >1.5
• Target Qd >1,000 mL/h to maximize ammonia clearance 1

When to Consider CVVH

• Predilution CVVH: When concerned about hemoconcentration and filter clotting at low blood flow rates, though this sacrifices 15% clearance efficiency 3
• Better for larger molecules: If concurrent removal of middle molecules (like beta-2-microglobulin) is needed, though this is rarely the priority in acute hyperammonemia 2

When to Use CVVHDF

• Limited added benefit: Despite theoretical advantages, CVVHDF shows no superior ammonia clearance in practice 4
• Consider if: Your institution's CRRT machine cannot achieve adequate dialysate flow rates for pure CVVHD (some pediatric circuits limit Qd to 1 L/h) 1

Critical Pitfalls to Avoid

1. Equipment limitations: Prismaflex and Fresenius pediatric circuits limit dialysate flow to 1 L/h, potentially requiring switch to intermittent HD for ammonia >1,000 μmol/L 1

2. Vascular access: The need for adequate vascular access is the main limitation—consider ECMO-assisted CRRT in low-birth-weight neonates with poor access 1

3. Temperature management: Always warm the dialysate to maintain hemodynamic stability in neonates 1

4. Ammonia clearance is slower than expected: Ammonia clearance is significantly less than urea or creatinine clearance (25 vs 50 vs 42 mL/min respectively, p=0.0001) 4. Don't assume ammonia will clear as rapidly as other small solutes.

5. Pre-treatment status matters most: The duration of hyperammonemic coma before starting dialysis is the most important prognostic factor—not the rate of ammonia clearance 1. Start early.

Practical Algorithm

For ammonia >1,000 μmol/L (1,703 μg/dL):

• Start with intermittent HD for rapid initial reduction (75% decrease in 3-4 hours) 1
• Transition to high-dose CVVHD once ammonia <200 μmol/L to prevent rebound 1

For ammonia 400-1,000 μmol/L:

• Initiate high-dose CVVHD directly (Qb 30-50 mL/min, Qd/Qb >1.5) 1

For ammonia 150-400 μmol/L with neurological deterioration:

• Start standard-dose CVVHD 1